Skip to main content
Thomas U Marron on Muck Rack

Thomas U Marron

As seen in: Nature, The BMJ, JAMA Oncology, Everyday Health, The Lancet, Healio, HemOnc Today, Cancer Discovery, Future Medicine, ONCOLOGY journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas U

Contact Thomas U, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply

|
By Brandon Block Verified, Thomas U Marron, Nicholas Gulati
| JAMA Oncology Verified
In Reply We welcome the opportunity to respond to the comments by Rhodes and Shoag regarding our recent article.1 The authors raise points that merit discussion, particularly those concerning unmeasured confounding, mortality ascertainment, and study design. First, the authors suggest that early separation of survival curves implies unmeasured confounding.
Open in Who Shared Issue with article?

A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0

|
By Nicholas Gulati, Brandon Block Verified, Jaanvi Mehta, Thomas U Marron
| JAMA Oncology Verified
The Common Terminology Criteria for Adverse Events (CTCAE) is the de facto framework for the reporting of adverse events (AEs) secondary to oncologic therapies.
Open in Who Shared Issue with article?

Author Correction: Innovative approaches for lung cancer screening and interception

|
By Jianjun Zhang, Matthew Park, Tej Pandya, Elaine Shum, Jia Yee Wu, Simon Heeke, Ramin Salehi-Rad, Thomas U Marron, Zhubo Wei, Hui Li, Torsten G. Blum, John Heymach, Steven M. Dubinett, Pan-Chyr Yang, Charles Swanton, Miriam Merad
| Nature Verified
Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-026-01131-4, published online 23 February 2026 In the version of the article initially published, in the second paragraph of the “cfDNA” section, the text “However, subsequent retrospective validation in a cohort of individuals eligible for lung cancer screening revealed a low PPV of 1.3%, probably owing to low specificity (58%).
Open in Who Shared Issue with article?
See all 75 licensed articles (169 Total)